No Data
No Data
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Huaxia Ophthalmology (301267): The 24Q1 performance growth rate has slowed, and the implementation of mergers and acquisitions is expected to increase annual results
Core view: Huaxia Ophthalmology announced the 2023 and 2024Q1 results. The company achieved operating income of 4,013 billion yuan in 2023, +24.12% year-on-year; net profit to mother was 666 million yuan, +29 million yuan year-on-year.
Huaxia Ophthalmology (301267): Steady growth in performance, endogenous extension improving national layout
Investment highlights The 2023 performance grew rapidly, and the overall performance was stable in 2024Q1. The company released the 2023 report and the 2024 quarterly report: it achieved revenue of 4,013 billion yuan and net profit to mother of 666 million yuan for the full year of 2023, compared with the same period last year
Huaxia Ophthalmology (301267): The 24Q1 results are in line with expectations and the acquisition of hospitals will increase performance
Incident: The company announced that in 2023, it achieved revenue of 4,013 billion yuan (+24.12%, indicating year-on-year growth rate, same below), net profit to mother of 666 million yuan (+29.60%), after deducting 6.62 billion yuan in net profit not attributable to mother
Huaxia Ophthalmology (301267): 1Q24 steady growth service network continues to expand
Against the backdrop of internal and external factors, 1Q24's performance grew steadily, and the company achieved revenue/net profit of 40.1/670 million yuan in 23 years (yoy +24.1%/+29.6%), and 1Q24 achieved revenue/net profit to mother
Dongguan Securities released a research report on April 25 stating that Huaxia Ophthalmology (301267.SZ) was given a purchase rating. The main reasons for the rating include: 1) the core business has maintained rapid growth; 2) all domestic regions have a
Dongguan Securities released a research report on April 25 stating that Huaxia Ophthalmology (301267.SZ) was given a purchase rating. The main reasons for the rating include: 1) the core business has maintained rapid growth; 2) all domestic regions have achieved relatively rapid positive revenue growth; 3) gross margin has continued to rise. (Mainichi Keizai Shimbun)
No Data